ResearcherLevine Cancer InstituteActive in the last 2 years

Declan Walsh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9310-1729; OpenAlex author ID A5036852179. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Improving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumor markers. First author DOI 10.4240/wjgs.v17.i1.101549 ↗
Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. Co-author DOI 10.1007/s00520-020-05876-1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Arunkumar Krishnan · 1 shared paper, 2025 · strength 0.54
- Paper Improving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumo… DOI 10.4240/wjgs.v17.i1.101549 ↗
Mohamed E. Salem · 1 shared paper, 2021 · strength 0.12
- Paper Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. DOI 10.1007/s00520-020-05876-1 ↗
Kunal C. Kadakia · 1 shared paper, 2021 · strength 0.12
- Paper Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. DOI 10.1007/s00520-020-05876-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.